• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    USANA Health Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

    12/23/24 9:03:09 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email
    usna-20241223
    FALSE000089626400008962642024-12-232024-12-23

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    _____________________
    FORM 8-K
    _____________________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of
    the Securities Exchange Act of 1934
    Date of Report (Date of Earliest Event Reported):
    December 23, 2024
    USANA HEALTH SCIENCES, INC.
    (Exact name of registrant as specified in its charter)
    Utah
    (State or other jurisdiction of incorporation)
    001-3502487-0500306
    (Commission File No.)(IRS Employer
    Identification No.)
    3838 West Parkway Boulevard
    Salt Lake City, Utah 84120
    (Address of principal executive offices, Zip Code)
    Registrant's telephone number, including area code: (801) 954-7100
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.001 par value per shareUSNANew York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
    Item 1.01. Entry into a Material Definitive Agreement.
    Agreement and Plan of Merger

    On December 23, 2024, USANA Health Sciences, Inc., a Utah corporation (“USANA” or the “Company”), entered into and consummated an Agreement and Plan of Merger (the “Merger Agreement”) by and among USANA, Karate Merger Sub, LLC, a Delaware limited liability company and a wholly-owned subsidiary of USANA (“Merger Sub”), Hiya Health Products, LLC, a Delaware limited liability company (“Hiya”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the representative of the unitholders of Hiya, to acquire a controlling interest in Hiya. Pursuant to the Merger Agreement, Merger Sub merged with and into Hiya (the “Merger”), with Hiya continuing as the surviving company (the “Surviving Company”). Hiya is a direct-to-consumer online retail business in the children’s vitamin, mineral, and supplement industry.

    Pursuant to the transactions contemplated by the Merger Agreement, at the effective time of the Merger (the “Effective Time”), upon the terms and subject to the conditions set forth in the Merger Agreement (a) USANA was issued Class A units of the Surviving Company (“Class A Units”) equal to 78.85% of the Surviving Company’s membership interests, (b) the membership interests in Hiya that were held by persons and entities that are accredited investors (as such term is defined in Rule 501(a) under the Securities Act of 1933, as amended) (the “Qualified Holders”), were cancelled and converted automatically into the right to receive cash consideration net of applicable tax withholding and deductions and Class B units of the Surviving Company (“Class B Units”) equal to an aggregate of 21.15% of the Surviving Company’s membership interests, and (c) all membership interests in Hiya that were held by persons and entities that were not Qualified Holders were cancelled and converted automatically into the right to receive cash consideration net of applicable tax withholding and deductions. Also at the Effective Time, options to acquire membership interests in Hiya were cancelled and terminated and the holders thereof received cash consideration, net of applicable tax withholding and deductions, in connection with the execution and delivery of an option termination agreement by such holders.

    The total consideration paid by USANA for its 78.85% membership interest in the Surviving Company consisted of $205 million in cash, subject to customary closing and post-closing purchase price adjustments in accordance with and subject to the terms and conditions of the Merger Agreement, sourced from $200 million cash on hand and the balance from borrowings under USANA’s existing credit facility. At the closing of the Merger, USANA deposited a portion of such consideration in escrow to secure certain indemnification obligations of the sellers and any post-closing adjustments to such consideration, in each case under the terms and conditions of the Merger Agreement.

    The Merger Agreement contains representations and warranties of the parties that are customary for a transaction of this type. The Merger Agreement also contains customary covenants and agreements, including, among others, certain publicity, confidentiality, information access, insurance and tax matters, certain cooperation commitments between the parties, and certain other matters.

    Amended and Restated Limited Liability Company Agreement

    Effective as of the Effective Time, USANA and the Qualified Holders entered into an amended and restated limited liability company agreement of the Surviving Company (the “LLC Agreement”). Pursuant to the LLC Agreement, the Surviving Company will be managed by managers (initially four), acting through majority approval, with one manager designated by the holders of Class B Units and the remaining managers designated by the holders of Class A Units, except that certain actions require the consent of the holders of Class A Units including (i) issuing additional Class A Units or Class B Units, (ii) changing the Surviving Company’s legal form, (iii) consummating a change of control, (iv) amending the certificate of formation of the Surviving Company, or (v) taking any other action that requires the consent of the holders of Class A Units. In addition, the LLC Agreement may not be amended, altered, or repealed in a manner that materially and adversely affects the powers, preferences, obligations or rights of the Class B Units in a manner disproportionate to the effect on the other then-outstanding classes and series of units without the consent of the holders of Class B Units.

    The LLC Agreement contains certain restrictions on transfers and provides for customary drag-along and tag-along rights, in each case, with respect to Class B Units. In addition, the holders of Class A Units have repurchase rights with respect to Class B Units on certain withdrawal events that include transfers of Class B Units in violation of the LLC Agreement, a



    breach of the LLC Agreement or any confidentiality, invention assignment, non-competition or non-solicitation agreement by a holder of Class B Units, and the occurrence of certain other prohibited actions taken by or with respect to holders of Class B Units.

    The LLC Agreement also grants (i) the Surviving Company the right to buy (the “Call Right”), and (ii) the holders of Class B Units the right, exercisable by holders of a majority of Class B Units, to cause the Surviving Company to purchase (the “Put Right”), half of the Class B Units beginning on April 30, 2028 and ending on the applicable Final Determination Date (as defined in the LLC Agreement) for the calendar year in which such right is exercised and any remaining Class B Units beginning on April 30, 2030 and ending on the applicable Final Determination Date for the calendar year in which such right is exercised. In addition on a Parent Change of Control (as defined in the LLC Agreement) the Surviving Company has a Call Right beginning on the date (the “CoC Agreement Date”) USANA enters into a definitive written agreement providing for a Parent Change of Control (as defined in the LLC Agreement) and ending on the date that is thirty days after the later of (i) the CoC Agreement Date and (ii) the applicable Final Determination Date for the calendar year in which such right is exercised. The purchase price for Class B Units pursuant to the Call Right, the Put Right, and any other repurchase rights under the LLC Agreement, is based on the Surviving Company’s Adjusted EBITDA (as defined in the LLC Agreement) for the calendar year immediately prior to the year in which such right is exercised, multiplied by the Company Value Reference Amount (as defined in the LLC Agreement).

    The foregoing descriptions of the Merger Agreement and the LLC Agreement contained in this Item 1.01 do not purport to be complete and are subject to, and qualified in their entirety by, the full text of such agreements. A copy of each of the Merger Agreement and the LLC Agreement is filed as Exhibit 2.1 and Exhibit 10.1, respectively, to this Current Report on Form 8-K, each of which is incorporated herein by reference.
    Item 2.01. Completion of Acquisition or Disposition of Assets.
    To the extent required, the information set forth above in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference in its entirety.
    Item 7.01. Regulation FD Disclosure.
    On December 23, 2024, USANA issued a press release announcing the Merger. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference.
    Also on December 23, 2024, USANA released an updated corporate presentation to the investor section of the Company’s website. A copy of the presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference.
    The information furnished pursuant to Item 7.01 (including Exhibit 99.1 and Exhibit 99.2) on this Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
    Item 9.01. Financial Statements and Exhibits.

    (a) Financial statements of business acquired
    The financial statements of Hiya required by this Item 9.01(a) is not included in this Current Report on Form 8-K. The Company intends to file such financial statements by amendment to this Current Report on Form 8-K not later than 71 calendar days after the date this Current Report on Form 8-K is required to be filed.
    (b) Pro forma financial information
    The pro forma financial information required by this Item 9.01(b) is not included in this Current Report on Form 8-K. The Company intends to file such pro forma financial information by amendment to this Current Report on Form 8-K not later than 71 calendar days after the date this Current Report on Form 8-K is required to be filed.
    Exhibit No.Description
    2.1*
    Agreement and Plan of Merger dated December 23, 2024 by and among USANA Health Sciences, Inc., MERGER SUB], Hiya Health Products, LLC, and Shareholder Representative Services LLC.
    10.1*
    Amended and Restated Limited Liability Company Agreement of Hiya Health Products, LLC dated December 23, 2024.
    99.1
    Press Release of USANA Health Sciences, Inc. dated December 23, 2024.
    99.2
    Corporate Presentation of USANA Health Sciences, Inc. dated December 23, 2024.
    *Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC;



    provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished.



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    USANA HEALTH SCIENCES, INC.
    By:/s/ G. Douglas Hekking
    G. Douglas Hekking, Chief Financial Officer
    Date: December 23, 2024

    Get the next $USNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    SEC Filings

    View All

    Amendment: USANA Health Sciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    2/11/26 4:51:10 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by USANA Health Sciences Inc.

    SCHEDULE 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    1/21/26 1:21:12 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    1/12/26 6:29:11 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended January 3, 2026. Key Financial and Operating Results   Q4 2025   Q4 2024   FY 2025   FY 2024 Net sales $226.2   $213.6   $925.3   $854.5 Net (loss) earnings* $-1.8   $4.5   $10.8   $42.0 Diluted EPS $-0.10   $0.23   $0.58   $2.19 Adjusted diluted EPS(1) $0.60   $0.64   $1.93   $2.59 Adjusted EBITDA(2) $27.3

    2/17/26 4:15:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Exec. Chairman/CEO Kevin Guest on Self-Renewal Day: Break Comfort Zones for Strategic Growth with Six Steps

    SALT LAKE CITY, Feb. 2, 2026 /PRNewswire/ -- As organizations face rapid market disruption and evolving leadership demands, Feb. 2 marks Self-Renewal Day, a pivotal time for business leaders to recalibrate strategies and personal development. "Growth does not happen by accident; it happens by choice," said  Kevin Guest, Executive Chairman & CEO at USANA Health Sciences (NYSE:USNA). "Self-Renewal Day is designed to prompt people to evaluate their lives, challenge complacency, and take deliberate steps toward personal and professional renewal." This annual observance is a critic

    2/2/26 7:05:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    The Compliance Imperative: Regulatory Moats Driving 2026 Asset Re-Ratings

    ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC. Baystreet.ca News Commentary  VANCOUVER, BC, Jan. 19, 2026 /PRNewswire/ -- The global consumer healthcare market is hitting a massive structural wall, projected to reach $362.17 billion in 2026[1]. In this high-stakes environment, commercial survival is no longer just about the product; it hinges on precision regulatory execution. Eight key regulatory and compliance pressures[2] are reshaping sector strategy, forcing a capital rotation into a first-mover cohort that includes Doseology Sciences Inc. (CSE:MOOD) (OTCPK:DOSEF) (FSE: VU70), Philip Morris (NYSE:PM), Celsius Holdings (NASDAQ:CELH), USANA Health Sciences (NYSE:USNA), and Medifast (NYSE:MED

    1/19/26 12:10:00 PM ET
    $CELH
    $MED
    $PM
    Beverages (Production/Distribution)
    Consumer Staples
    Packaged Foods
    Medicinal Chemicals and Botanical Products

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF LEGAL OFFICER Foukas Joshua sold $95,220 worth of shares (4,461 units at $21.34), closing all direct ownership in the company (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    2/23/26 7:12:29 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by CHIEF INFORMATION OFFICER Benedict Peter

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    2/23/26 7:06:24 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Armstrong Kathryn Michelle

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    2/23/26 7:03:50 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sidoti initiated coverage on USANA

    Sidoti initiated coverage of USANA with a rating of Buy

    6/23/23 9:12:38 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA downgraded by Jefferies with a new price target

    Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

    7/7/22 9:35:48 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    DA Davidson initiated coverage on USANA with a new price target

    DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

    4/14/22 7:45:27 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Financials

    Live finance-specific insights

    View All

    USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended January 3, 2026. Key Financial and Operating Results   Q4 2025   Q4 2024   FY 2025   FY 2024 Net sales $226.2   $213.6   $925.3   $854.5 Net (loss) earnings* $-1.8   $4.5   $10.8   $42.0 Diluted EPS $-0.10   $0.23   $0.58   $2.19 Adjusted diluted EPS(1) $0.60   $0.64   $1.93   $2.59 Adjusted EBITDA(2) $27.3

    2/17/26 4:15:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Provides Preliminary Fiscal Year 2025 Net Sales and Issues Initial Fiscal Year 2026 Net Sales Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary fiscal year 2025 net sales and initial net sales guidance for fiscal year 2026 ahead of its presentation at the 28th Annual ICR Conference. At the conference, Doug Hekking, CFO, and Walter Noot, COO, will discuss USANA's strategy, including the Company's initial fiscal year 2026 sales outlook. Preliminary Fiscal Year 2025 Net Sales Results The Company currently anticipates fiscal year 2025 consolidated net sales of approximately $925 million, ahead of its most recently issued guidance of approximately $920 million. Initial Fiscal Year 2026 Net Sales Outlook The Company is issuing its initial net sales outlook for fi

    1/12/26 6:15:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Reports Third Quarter 2025 Results and Updates Full-Year Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 27, 2025. Key Financial Results Third Quarter 2025 vs. Third Quarter 2024 Net sales of $214 million versus $200 million, representing 7% year-over-year growth. Net loss of -$6.5 million versus net earnings of $10.6 million. Diluted EPS of -$0.36 as compared with $0.56. Adjusted diluted EPS(1) of -$0.15 as compared with $0.56. Adjusted EBITDA(2) of $13.8 million versus $24.6 million. Direct selling Active Customers of 388,000 versus 452,000. Hiya Active Monthly Subscribers of 193,400. Q3 2025 Financial Performance Consolidated Results

    10/22/25 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    View All

    Kevin Guest Returns to USANA Health Sciences as CEO

    USANA Health Sciences, Inc. (NYSE:USNA) announced today a leadership transition as part of the Company's ongoing commitment to accelerating growth and enhancing shareholder value. Kevin Guest is returning to lead the Company as Chief Executive Officer, effective immediately. Mr. Guest, who has spent more than three decades at the Company, including eight years as CEO and the last three years as Executive Chairman, has agreed to again serve as USANA's CEO and will continue serving as Chairman. Mr. Guest succeeds Jim Brown, who has stepped down from his position of CEO and President. "We thank Jim for his contributions and his leadership over the past 19 years and in his role as CEO over th

    1/8/26 9:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Solstice Advance Materials and Qnity Electronics Set to Join S&P 500; Others to Join S&P SmallCap 600

    NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c

    10/27/25 6:10:00 PM ET
    $CAL
    $DD
    $EMN
    Shoe Manufacturing
    Consumer Discretionary
    Major Chemicals
    Industrials

    USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

    SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

    4/1/25 7:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/24 10:49:58 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/23 11:26:45 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/11/22 3:48:24 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care